Veru Chief Scientific Officer Gary Barnette acquires $4,841.82 in common sharesPUBT·21 hours agoVERU-3.04%
Pre-market hot trades in US stocks: Veru pre-market down 8.18%; USA Rare Earth pre-market down 7.20%Price Alert·Aug 11 at 05:13 AMVERU-3.04%USAR-2.49%
Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial ProgressUnusual Whales·Aug 10 at 06:08 AMVERU-3.04%
Veru FY26 Q3 net loss narrows to $7 million; R&D expense rises 44% to $4.4 millionPUBT·Aug 10 at 05:30 AMVERU-3.04%
Veru wins US patent allowance for enobosarm-semaglutide weight-loss regimen claimsPUBT·Aug 4 at 07:35 AMVERU-3.04%
Veru schedules conference call on quarterly financial results and business updatePUBT·Aug 3 at 07:33 AMVERU-3.04%
Veru CEO Steiner joins Canaccord Genuity Growth Investors Conference fireside chatPUBT·Jul 30 at 07:33 AMVERU-3.04%
Cross-Sector M&A Accelerates as U.S. Mid-Caps Push for RestructuringGlobal Report·Jul 28 at 04:12 AMFXHO-4.82%FNVTF
Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss | VERU Stock NewsStockTitan·Jul 26 at 11:10 PMVERU-3.04%
Veru completes Phase 2b PLATEAU trial enrolling 250 patients for weight loss with Enobosarm and Semaglutide combo.Unusual Whales·Jul 27 at 07:12 AMVERU-3.04%
